Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Zidovudine (ZDV) 是一种核苷逆转录酶抑制剂,有潜力研究 HIV 感染。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
50 mg | ¥ 343 | 现货 | ||
100 mg | ¥ 493 | 现货 | ||
200 mg | ¥ 726 | 现货 | ||
500 mg | ¥ 1,230 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 547 | 现货 |
产品描述 | Zidovudine (ZDV) is a synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zidovudine inhibits DNA polymerase, resulting in the inhibition of DNA replication and cell death. This agent also decreases levels of available pyrimidines. |
体内活性 | Intravitrous injection of the NRTIs Lamivudine (3TC), Zidovudine (AZT), or Abacavir (ABC) suppresses the laser-induced choroidal neovascularization (CNV) in wild-type mice compared to PBS vehicle. The mean level of VEGF-A in the RPE/choroid, which peaks on day 3 after laser injury, is significantly reduced in 3TC-, AZT- and ABC-treated eyes compared with control eyes in wild-type mice, but not inP2rx7-/- mice[6]. |
细胞实验 | Zidovudine is prepared in DMSO (10 mM) and stored, and then diluted with appropriate medium before use[1]. Assays are performed in all cell types in the presence of titrating concentrations of ARV. 5,000 SVG, 2,500 PFA, 200,000 PBMC, or 50,000 MDM cells/well are seeded into triplicate wells of 96-well plates. Twenty-four hours later, the culture medium is removed and replaced with medium containing the ARV or DMSO (0.5% vol/vol), and equivalent TCID50 infectious units of luciferase reporter virus are added to the cells. After a 16 h incubation at 37°C, the initial viral inoculum is removed and replaced with culture medium containing the same antiretroviral drug (ARV) or DMSO (0.5% vol/vol) concentrations. At 72 h post infection, the medium is aspirated, the cells are lysed and HIV-1 infection measured using the Luciferase Assay System. Luminescence is measured using a FLUOStar Optima microplate reader. Inhibition curves and the 50% (EC50) and 90% (EC90) effective concentrations are determined by nonlinear regression analysis, using GraphPad Prism software[1]. |
别名 | Azidothymidine, NSC 602670, ZDV, 齐多夫定, AZT, 叠氮胸苷 |
分子量 | 267.24 |
分子式 | C10H13N5O4 |
CAS No. | 30516-87-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 13.4 mg/mL (50 mM)
DMSO: 26.7 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 3.742 mL | 18.7098 mL | 37.4195 mL | 93.5489 mL |
5 mM | 0.7484 mL | 3.742 mL | 7.4839 mL | 18.7098 mL | |
10 mM | 0.3742 mL | 1.871 mL | 3.742 mL | 9.3549 mL | |
20 mM | 0.1871 mL | 0.9355 mL | 1.871 mL | 4.6774 mL | |
50 mM | 0.0748 mL | 0.3742 mL | 0.7484 mL | 1.871 mL | |
DMSO | 100 mM | 0.0374 mL | 0.1871 mL | 0.3742 mL | 0.9355 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Zidovudine 30516-87-1 DNA Damage/DNA Repair Microbiology/Virology Proteases/Proteasome HIV Protease Reverse Transcriptase Telomerase CRISPR/Cas9 HIV Azidothymidine NSC 602670 inhibit ZDV Human immunodeficiency virus 齐多夫定 AZT Inhibitor NSC602670 叠氮胸苷 NSC-602670 inhibitor